Back to News
Market Impact: 0.42
Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Cogent Biosciences' NDA for bezuclastinib in adults with advanced systemic mastocytosis has been accepted by the FDA. The agency set a PDUFA target action date of June 29, 2027, advancing the drug into the formal U.S. regulatory review process and providing a defined potential approval catalyst for COGT.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
COGT0.75
More News
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- US Senate crypto bill collapses in blow to industry
- BlackRock’s Fink, Blackstone’s Gray Back Carney’s Canada Investment Push
- Factbox-How AI leaders and world governments react to ’AI doom’ fears
- ‘The end of the keyboard is near’: Christian Klein predicts voice translation will be the next workplace advantage
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate AI Report Writers for Financial Analysis
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements